Application of brutinib and combined pharmaceutical composition thereof in treatment of leukemia

By combining brigatinib with veneclade, cytarabine, or daunorubicin, the problems of drug resistance and relapse in existing technologies have been solved, providing significant therapeutic effects and synergistic therapeutic benefits. This approach improves the treatment efficacy for leukemia compared to existing drug combinations.

CN121265619APending Publication Date: 2026-01-06SHENZHEN UNIV
0 Cites 0 Cited by

Patent Information

Application Number
CN202511753451.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-11-26
Publication Date
2026-01-06

AI Technical Summary

Technical Problem

Existing drugs for treating leukemia are prone to drug resistance, leading to relapse and treatment failure. There is a lack of effective combination therapy regimens to overcome the drug resistance problem.

Method used

By combining brigatinib with veneclade, cytarabine, or daunorubicin in different proportions, pharmaceutically acceptable salts were formed for the preparation of drug compositions and formulations for the treatment of leukemia. The synergistic effect was verified by calculating the CI index using CalcuSyn software.

Benefits of technology

It significantly inhibits the proliferation of leukemia cells and promotes their apoptosis, providing a more effective treatment option, improving the treatment effect for leukemia patients, and opening up new treatment avenues.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses application of brutinib and a combined pharmaceutical composition thereof in treatment of leukemia, and the leukemia comprises acute myelogenous leukemia, chronic myelogenous leukemia, T acute lymphoblastic leukemia and B acute lymphoblastic leukemia. The invention creatively finds that the brutinib has a remarkable synergistic effect on treatment of the leukemia when being combined with the vinca, the cytarabine or the daunorubicin for use, and a brand new drug combination scheme provided by the invention provides a more effective drug combination choice for treatment of the leukemia, and is expected to improve the treatment effect of patients with the leukemia.
Need to check novelty before this filing date? Find Prior Art